Tom-
I noticed GERN mentioned in that press release.
But this, from a recent press release is why I like to include ARIA in the stem cell group:
ARIAD intends to establish its RAGE technology - along with its proprietary gene regulation technologies, ARGENT and RAPID - as the technologies of choice for biotechnology and
pharmaceutical companies to use in their genomics, proteomics, and drug discovery programs and in therapeutic protein manufacturing.
Copies of the new ARIAD patent (U.S. Patent No. 6,117,689), as well as a prior patent relating to the RAGE technology (U.S. Patent No. 6,015,709) are available on the World Wide Web at
uspto.gov.
ARIAD Pharmaceuticals, Inc. (www.ariad.com) is a leader in the discovery and development of gene therapy, cell therapy, stem cell therapy and protein therapy products featuring dose-dependent
regulation by small-molecule drugs, as well as small-molecule inhibitors of signal transduction.
For full text, see biz.yahoo.com |
